Overall, these real-world clinical outcome data in a heterogeneous population of patients with ABC add to the totality of clinical and real-world evidence that support the use of palbociclib + ET in patients with HR+/HER2− ABC. This evidence concerns the gene HR and aneurysmal bone cyst.